tretinoin for Myelodysplastic Syndrome

"Tretinoin, while most commonly used to treat refractory anemias, can also be taken as medication for various other conditions including keratinization disorders of the feet and severe cystic acne."

"This trial allows anyone aged 18 or above to enroll, with the maximum age limit set at 120 years old."

"The clinicaltrials.gov website reveals that this trial is no longer recruiting patients. The posting date was July 1, 2006 and the last edit was on May 9, 20212. There are, however, 1799 other trials which are still looking for participants."

"Myelodysplastic syndromes patients that meet the following requirements are encouraged to participate in this trial. To be eligible, participants must be between 18-120 years old and have responded to decitabine therapy if they have received it in the past (as per International Working Group Response Criteria). Other notable inclusion criteria include being ineligible for transplantation and having either untreated or treated intermediate-1 risk disease, Intermediate-2 risk disease, High-risk disease, or No treatment-related MDS."

"At the moment, this trial is not looking for new patients. However, it's worth noting that this study was last updated on May 9th, 2022 and initially posted 16 years ago on July 1st, 2006. If you're interested in other trials, there are currently 1671 studies actively recruiting patients with myelodysplastic syndromes and 128 trials for tretinoin admitting participants."

"There are currently 128 ongoing trials for tretinoin, with 21 of them in Phase 3. The vast majority of these studies are taking place in Reggio Emilia and Foggia, though there are a total of 1,783 locations running trials for tretinoin."